Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Over the last 12 months, insiders at Elevation Oncology, Inc. have bought $0 and sold $0 worth of Elevation Oncology, Inc. stock.
On average, over the past 5 years, insiders at Elevation Oncology, Inc. have bought $26M and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 187,500 shares for transaction amount of $3M was made by Aisling Capital IV, LP (10 percent owner) on 2021‑06‑29.
2022-05-25 | Sale | Royston Aaron | 702,737 3.1622% | $4.12 | $2.9M | -69.80% | ||
2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 187,500 22.5074% | $16.00 | $3M | -56.00% | ||
2021-06-29 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 625,000 75.0247% | $16.00 | $10M | -56.00% | ||
2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 312,500 37.5123% | $16.00 | $5M | -56.00% | ||
2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 250,000 30.0099% | $16.00 | $4M | -56.00% | ||
2021-06-29 | Cormorant Asset Management, LP | 250,000 30.0099% | $16.00 | $4M | -56.00% |
Aisling Capital IV, LP | 10 percent owner | 2834910 6.6838% | $2.35 | 1 | 0 | <0.0001% |
venBio Global Strategic Fund III, L.P. | 10 percent owner | 2608167 6.1492% | $2.35 | 1 | 0 | <0.0001% |
Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2370142 5.588% | $2.35 | 1 | 0 | <0.0001% |
Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2307642 5.4407% | $2.35 | 1 | 0 | <0.0001% |
Cormorant Asset Management, LP | 2233168 5.2651% | $2.35 | 1 | 0 | <0.0001% | |
Royston Aaron | 1905430 4.4924% | $2.35 | 0 | 1 |
Farallon Capital | $19.94M | 7.11 | 3.89M | New | +$19.94M | 0.14 | |
Point72 Asset Management | $17.28M | 6.17 | 3.37M | New | +$17.28M | 0.03 | |
Tang Capital Management, LLC | $15.7M | 5.6 | 3.06M | -16.57% | -$3.12M | 0.06 | |
Balyasny Asset Management Llc | $15.67M | 5.59 | 3.06M | New | +$15.67M | 0.04 | |
Aisling Capital Management LP | $14.54M | 5.19 | 2.83M | 0% | +$0 | 4.98 | |
venBio | $13.83M | 4.93 | 2.7M | -7.49% | -$1.12M | 4.91 | |
Braidwell Lp | $12.2M | 4.35 | 2.38M | New | +$12.2M | 0.69 | |
Darwin Global Management Ltd | $11.97M | 4.27 | 2.33M | New | +$11.97M | 1.78 | |
Bvf Inc Il | $11.86M | 4.23 | 2.31M | 0% | +$0 | 0.09 | |
Citadel Advisors LLC | $8.05M | 2.87 | 1.57M | +165.36% | +$5.02M | 0.01 | |
The Vanguard Group | $7.86M | 2.8 | 1.53M | +30.8% | +$1.85M | <0.0001 | |
Artal Group S A | $7.76M | 2.77 | 1.51M | New | +$7.76M | 0.04 | |
Hudson Bay Capital Management LP | $7.75M | 2.77 | 1.51M | +176.57% | +$4.95M | 0.08 | |
Palo Alto Investors Lp | $6.91M | 2.47 | 1.35M | New | +$6.91M | 0.78 | |
Affinity Asset Advisors | $6.51M | 2.32 | 1.27M | New | +$6.51M | 1.16 | |
Logos Global Management Lp | $5.13M | 1.83 | 1M | New | +$5.13M | 0.55 | |
OrbiMed | $4.83M | 1.72 | 941,275 | -37.25% | -$2.87M | 0.1 | |
Laurion Capital Management LP | $4.56M | 1.63 | 888,889 | New | +$4.56M | 0.13 | |
Walleye Capital | $4.04M | 1.44 | 786,584 | New | +$4.04M | 0.01 | |
Millennium Management LLC | $3.43M | 1.22 | 668,573 | -77.64% | -$11.91M | <0.01 | |
Goldman Sachs | $2.83M | 1.01 | 551,079 | New | +$2.83M | <0.01 | |
Velan Capital | $2.55M | 0.91 | 497,299 | 0% | +$0 | 1.39 | |
Sphera Fund | $2.21M | 0.79 | 430,000 | -52.22% | -$2.41M | 0.37 | |
Geode Capital Management | $1.79M | 0.64 | 348,433 | +51.4% | +$607,017.65 | <0.0001 | |
GHOST TREE CAPITAL LLC | $1.28M | 0.46 | 250,000 | New | +$1.28M | 0.42 | |
Bank of America | $1.26M | 0.45 | 245,332 | +58.82% | +$466,127.13 | <0.0001 | |
Schonfeld Group | $905,091.00 | 0.32 | 176,431 | +1,151.28% | +$832,758.00 | 0.01 | |
BlackRock | $881,852.00 | 0.32 | 171,901 | +113.08% | +$467,984.18 | <0.0001 | |
Ikarian Capital LLC | $759,697.00 | 0.27 | 148,089 | -87.36% | -$5.25M | 0.22 | |
Qube Research & Technologies | $732,179.00 | 0.26 | 142,725 | New | +$732,179.00 | <0.01 | |
JPMorgan Chase | $703,882.00 | 0.25 | 137,209 | +56,833.19% | +$702,645.67 | <0.0001 | |
Hrt Financial Llc | $683,000.00 | 0.24 | 133,268 | New | +$683,000.00 | <0.01 | |
Marshall Wace | $680,731.00 | 0.24 | 132,696 | New | +$680,731.00 | <0.01 | |
UBS | $628,758.00 | 0.22 | 122,565 | -4.59% | -$30,266.98 | <0.0001 | |
Man Group Plc | $621,920.00 | 0.22 | 121,232 | New | +$621,920.00 | <0.01 | |
Citigroup | $613,076.00 | 0.22 | 119,508 | New | +$613,076.00 | <0.01 | |
State Street | $567,378.00 | 0.2 | 110,600 | +162.71% | +$351,405.00 | <0.0001 | |
Bridgeway Capital Management | $546,345.00 | 0.2 | 106,500 | New | +$546,345.00 | 0.01 | |
Prelude Capital | $514,549.00 | 0.18 | 100,302 | New | +$514,549.00 | 0.04 | |
Jane Street Capital | $404,757.00 | 0.14 | 78,900 | New | +$404,757.00 | <0.0001 | |
Squarepoint Ops LLC | $355,514.00 | 0.13 | 69,301 | New | +$355,514.00 | <0.01 | |
Dimensional Fund Advisors | $350,625.00 | 0.13 | 68,348 | New | +$350,625.00 | <0.0001 | |
Northern Trust | $332,414.00 | 0.12 | 64,798 | +45.5% | +$103,954.40 | <0.0001 | |
Polar Asset Management Partners Inc | $280,611.00 | 0.1 | 54,700 | New | +$280,611.00 | 0.01 | |
Boothbay Fund Management LLC | $201,999.00 | 0.07 | 39,376 | -84.66% | -$1.11M | 0.01 | |
American Century Investments | $162,211.00 | 0.06 | 31,620 | New | +$162,211.00 | <0.0001 | |
Brevan Howard Capital Management Lp | $145,477.00 | 0.05 | 28,358 | New | +$145,477.00 | 0.01 | |
Morgan Stanley | $144,010.00 | 0.05 | 28,072 | +719.14% | +$126,429.41 | <0.0001 | |
Bank of Montreal | $115,938.00 | 0.04 | 22,600 | New | +$115,938.00 | <0.0001 | |
Y Intercept Hong Kong Ltd | $111,860.00 | 0.04 | 21,805 | New | +$111,860.00 | 0.01 |